BRCA-话题@MedSci

#BRCA#

135篇内容 | 4604人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1594022, encodeId=ea821594022b6, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=Matulonis教授：PARP抑制剂——BRCA相关癌症的克星, objectType=article, longId=123424, objectId=07e11234248f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=07e11234248f, replyNumber=0, likeNumber=82, createdTime=2017-12-16, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=07e11234248f, moduleTitle=Matulonis教授：PARP抑制剂——BRCA相关癌症的克星, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=07e11234248f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594021, encodeId=2af2159402185, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=Nat Commun：新研究揭示BRCA癌细胞最后的“生存策略”, objectType=article, longId=122248, objectId=235e12224865, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=235e12224865, replyNumber=0, likeNumber=89, createdTime=2017-12-06, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=235e12224865, moduleTitle=Nat Commun：新研究揭示BRCA癌细胞最后的“生存策略”, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=235e12224865)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594020, encodeId=7558159402021, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=JAMA Surgery:NSM可有效降低BRCA突变人群乳腺癌风险, objectType=article, longId=114051, objectId=326b114051c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=326b114051c1, replyNumber=0, likeNumber=0, createdTime=2017-09-26, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=326b114051c1, moduleTitle=JAMA Surgery:NSM可有效降低BRCA突变人群乳腺癌风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=326b114051c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594019, encodeId=0d0215940198e, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=Oncologist 等：肥胖类型对乳腺癌风险影响因HR状态而异/ NSM可有效降低BRCA突变人群乳腺癌风险/根据患者年龄及肿瘤分子分型预测腋窝手术强度, objectType=article, longId=114049, objectId=ca7411404999, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ca7411404999, replyNumber=0, likeNumber=62, createdTime=2017-09-26, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ca7411404999, moduleTitle=Oncologist 等：肥胖类型对乳腺癌风险影响因HR状态而异/ NSM可有效降低BRCA突变人群乳腺癌风险/根据患者年龄及肿瘤分子分型预测腋窝手术强度, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ca7411404999)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594018, encodeId=da77159401878, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=JNCI：BRCA突变携带者行预防性输卵管卵巢切除术后，子宫内膜浆液性癌的发病风险降低了吗？, objectType=article, longId=111006, objectId=6d8a11100618, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6d8a11100618, replyNumber=0, likeNumber=35, createdTime=2017-08-28, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6d8a11100618, moduleTitle=JNCI：BRCA突变携带者行预防性输卵管卵巢切除术后，子宫内膜浆液性癌的发病风险降低了吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6d8a11100618)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594017, encodeId=62bd159401eae, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=NEJM：BRCA生殖系突变阳性的晚期乳腺癌：奥拉帕尼（Olaparib）有力回天？, objectType=article, longId=108612, objectId=fcb31086129c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fcb31086129c, replyNumber=0, likeNumber=116, createdTime=2017-08-13, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fcb31086129c, moduleTitle=NEJM：BRCA生殖系突变阳性的晚期乳腺癌：奥拉帕尼（Olaparib）有力回天？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fcb31086129c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594016, encodeId=0105159401658, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=NEJM：Olaparib为有BRCA突变的转移性乳腺癌患者带来希望, objectType=article, longId=108450, objectId=b39c1084500d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b39c1084500d, replyNumber=0, likeNumber=0, createdTime=2017-08-12, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b39c1084500d, moduleTitle=NEJM：Olaparib为有BRCA突变的转移性乳腺癌患者带来希望, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b39c1084500d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594015, encodeId=c13c15940153c, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=Decision Analysis：安吉丽娜·朱莉正确？优化突变型BRCA携带者的癌症预防策略, objectType=article, longId=106993, objectId=e3d410699350, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e3d410699350, replyNumber=0, likeNumber=71, createdTime=2017-07-29, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e3d410699350, moduleTitle=Decision Analysis：安吉丽娜·朱莉正确？优化突变型BRCA携带者的癌症预防策略, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e3d410699350)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594014, encodeId=3a87159401480, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=Lancet Oncol：奥拉帕尼片剂可用于铂敏感、复发性卵巢癌及BRCA1/2突变(SOLO2/ENGOT-Ov21/)患者的维持治疗, objectType=article, longId=106877, objectId=eba21068e7a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eba21068e7a6, replyNumber=0, likeNumber=87, createdTime=2017-07-28, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eba21068e7a6, moduleTitle=Lancet Oncol：奥拉帕尼片剂可用于铂敏感、复发性卵巢癌及BRCA1/2突变(SOLO2/ENGOT-Ov21/)患者的维持治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eba21068e7a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594013, encodeId=496e1594013d1, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=除BRCA1和BRCA2外，乳腺癌遗传易感性还与哪些突变相关？, objectType=article, longId=106502, objectId=594610650285, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=594610650285, replyNumber=0, likeNumber=83, createdTime=2017-07-26, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=594610650285, moduleTitle=除BRCA1和BRCA2外，乳腺癌遗传易感性还与哪些突变相关？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=594610650285)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594012, encodeId=c20615940122b, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=JAMA:遗传咨询的茫茫前路，BRCA致癌性远比认识复杂, objectType=article, longId=106275, objectId=0ac21062e5e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0ac21062e5e4, replyNumber=0, likeNumber=82, createdTime=2017-07-23, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0ac21062e5e4, moduleTitle=JAMA:遗传咨询的茫茫前路，BRCA致癌性远比认识复杂, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0ac21062e5e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594011, encodeId=a066159401110, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=BRCA数据解读中国专家共识, objectType=article, longId=105961, objectId=30eb1059614c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=30eb1059614c, replyNumber=0, likeNumber=34, createdTime=2017-07-20, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=30eb1059614c, moduleTitle=BRCA数据解读中国专家共识, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=30eb1059614c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594010, encodeId=440a1594010c7, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=JAMA Oncol.:BRCA1/2基因突变状态能否预测三阴乳腺癌新辅助化疗效果？, objectType=article, longId=105944, objectId=e78710594471, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e78710594471, replyNumber=0, likeNumber=98, createdTime=2017-07-20, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e78710594471, moduleTitle=JAMA Oncol.:BRCA1/2基因突变状态能否预测三阴乳腺癌新辅助化疗效果？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e78710594471)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594009, encodeId=03f21594009b9, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=CLIN CANCER RES：三阴性乳腺癌铂基新辅助化疗期间肿瘤BRCA1反向突变增加且与治疗抵抗有关, objectType=article, longId=105038, objectId=7f6e10503832, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7f6e10503832, replyNumber=0, likeNumber=89, createdTime=2017-07-11, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7f6e10503832, moduleTitle=CLIN CANCER RES：三阴性乳腺癌铂基新辅助化疗期间肿瘤BRCA1反向突变增加且与治疗抵抗有关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7f6e10503832)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594008, encodeId=03f1159400826, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=Sci Rep：前列腺癌中BRCA2 的突变和紫杉醇抗性, objectType=article, longId=104743, objectId=bdb9104e4325, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bdb9104e4325, replyNumber=0, likeNumber=79, createdTime=2017-07-07, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bdb9104e4325, moduleTitle=Sci Rep：前列腺癌中BRCA2 的突变和紫杉醇抗性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bdb9104e4325)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594007, encodeId=dc23159400e79, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=聚焦卵巢癌精准诊疗发展：BRCA基因检测率低，精准诊疗水平待提高, objectType=article, longId=104218, objectId=d946104218fb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d946104218fb, replyNumber=0, likeNumber=107, createdTime=2017-07-02, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d946104218fb, moduleTitle=聚焦卵巢癌精准诊疗发展：BRCA基因检测率低，精准诊疗水平待提高, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d946104218fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594006, encodeId=3c7e1594006f3, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=JAMA:BRCA1/2突变携带者，不同年龄阶段的患癌风险到底有多大？, objectType=article, longId=103121, objectId=6c24103121f0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6c24103121f0, replyNumber=0, likeNumber=64, createdTime=2017-06-25, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6c24103121f0, moduleTitle=JAMA:BRCA1/2突变携带者，不同年龄阶段的患癌风险到底有多大？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6c24103121f0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594005, encodeId=b4711594005a7, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=ASCO2017:从临床组织和液体活检样本中发现了前列腺癌的BRCA1/2基因回复突变, objectType=article, longId=100929, objectId=567b1009293e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=567b1009293e, replyNumber=0, likeNumber=73, createdTime=2017-06-08, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=567b1009293e, moduleTitle=ASCO2017:从临床组织和液体活检样本中发现了前列腺癌的BRCA1/2基因回复突变, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=567b1009293e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594004, encodeId=407b1594004d7, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=ASCO2017：BRCA突变携带者进行治疗和预防联合乳房切除术的结果分析, objectType=article, longId=100894, objectId=dd7610089477, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dd7610089477, replyNumber=0, likeNumber=85, createdTime=2017-06-08, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dd7610089477, moduleTitle=ASCO2017：BRCA突变携带者进行治疗和预防联合乳房切除术的结果分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dd7610089477)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594003, encodeId=5698159400345, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=NEJM：奥拉帕利治疗BRCA突变的转移性乳腺癌患者疗效如何？, objectType=article, longId=100831, objectId=15ac10083129, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=15ac10083129, replyNumber=0, likeNumber=0, createdTime=2017-06-07, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=15ac10083129, moduleTitle=NEJM：奥拉帕利治疗BRCA突变的转移性乳腺癌患者疗效如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=15ac10083129)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

BRCA

2020-05-29

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

Matulonis教授：PARP抑制剂——BRCA相关癌症的克星

2017-12-16

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

Nat Commun：新研究揭示BRCA癌细胞最后的“生存策略”

2017-12-06

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

JAMA Surgery:NSM可有效降低BRCA突变人群乳腺癌风险

2017-09-26

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

Oncologist 等：肥胖类型对乳腺癌风险影响因HR状态而异/ NSM可有效降低BRCA突变人群乳腺癌风险/根据患者年龄及肿瘤分子分型预测腋窝手术强度

2017-09-26

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

JNCI：BRCA突变携带者行预防性输卵管卵巢切除术后，子宫内膜浆液性癌的发病风险降低了吗？

2017-08-28

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

NEJM：BRCA生殖系突变阳性的晚期乳腺癌：奥拉帕尼（Olaparib）有力回天？

2017-08-13

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

NEJM：Olaparib为有BRCA突变的转移性乳腺癌患者带来希望

2017-08-12

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

Decision Analysis：安吉丽娜·朱莉正确？优化突变型BRCA携带者的癌症预防策略

2017-07-29

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

Lancet Oncol：奥拉帕尼片剂可用于铂敏感、复发性卵巢癌及BRCA1/2突变(SOLO2/ENGOT-Ov21/)患者的维持治疗

2017-07-28

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

除BRCA1和BRCA2外，乳腺癌遗传易感性还与哪些突变相关？

2017-07-26

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

JAMA:遗传咨询的茫茫前路，BRCA致癌性远比认识复杂

2017-07-23

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

BRCA数据解读中国专家共识

2017-07-20

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

JAMA Oncol.:BRCA1/2基因突变状态能否预测三阴乳腺癌新辅助化疗效果？

2017-07-20

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

CLIN CANCER RES：三阴性乳腺癌铂基新辅助化疗期间肿瘤BRCA1反向突变增加且与治疗抵抗有关

2017-07-11

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

Sci Rep：前列腺癌中BRCA2 的突变和紫杉醇抗性

2017-07-07

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

聚焦卵巢癌精准诊疗发展：BRCA基因检测率低，精准诊疗水平待提高

2017-07-02

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

JAMA:BRCA1/2突变携带者，不同年龄阶段的患癌风险到底有多大？

2017-06-25

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

ASCO2017:从临床组织和液体活检样本中发现了前列腺癌的BRCA1/2基因回复突变

2017-06-08

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

ASCO2017：BRCA突变携带者进行治疗和预防联合乳房切除术的结果分析

2017-06-08

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

NEJM：奥拉帕利治疗BRCA突变的转移性乳腺癌患者疗效如何？

2017-06-07

科室
- - 订阅+
  - 更多科室
工具
服务